Study on the Relationship Between Peripheral Blood miRNA and Risk and Severity of Alzheimer's Disease

Plain-language summary

This study examines the relationship between peripheral blood miRNA levels and the risk and severity of Alzheimer's disease. It is enrolling patients diagnosed with Alzheimer's disease and healthy volunteers without cognitive impairment. It is being run as a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Jiajie Chen

Intervention

exposure

Start date

4/3/2021

Estimated completion

12/30/2026

Countries

China

Related genes

Locations

• Wuhan, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Alzheimer's disease patients:

* Meet the diagnostic criteria of NINCDS-ADRDA for AD
* Clinical Dementia Scale (CDR) score ≥0.5

Healthy volunteers:

* No complaints or symptoms of cognitive impairment
* MMSE score is higher than the threshold value

Exclusion Criteria:

Alzheimer's disease patients:

* Dementia or cognitive impairment due to other diseases
* Combined with delirium
* A history of drug abuse
* Severe deafness, aphasia and other impact scale score

Healthy volunteers:

* had an organic brain lesion
* Suffering from other major physical diseases: such as severe immune diseases